A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women
Latest Information Update: 19 Mar 2025
At a glance
Most Recent Events
- 30 Sep 2024 According to Angitia Biopharmaceuticals media release, data from the study were presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR) on September 27-30, 2024, in Toronto, ON, Canada.
- 30 Sep 2024 Results published in the Angitia Biopharmaceuticals Media Release.
- 16 Sep 2024 According to Angitia Biopharmaceuticals media release, data from the study will be presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR) September 27-30, 2024, in Toronto, ON, Canada.